Health Blueprint

Back to Longevity News

News summary

Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

Source: PR Newswire • Published: 02 Nov 2026, 06:47

Summarized by Masters of Longevity from PR Newswire.

Fresenius secured exclusive development access to up to 37 biosimilar candidates.

Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Key Takeaways
  • Fresenius has exclusive rights to develop up to 37 candidates.
  • The portfolio can increase from 29 to as many as 66 molecules.
  • This is observational pipeline expansion and not proof of efficacy.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?